Tavapadon — Safety, Research, Risks & Legal Status

Q: What makes tavapadon different from older Parkinson's drugs like pramipexole or ropinirole?

Older dopamine agonists used in Parkinson's disease primarily target D2 and D3 receptors. D3 agonism in particular is associated with impulse control disorders and excessive daytime sleepiness. Tavapadon selectively targets D1 and D5 receptors instead, which is hypothesized to provide motor benefit through the direct striatal pathway while avoiding D2/D3-driven side effects. Phase 3 trial data to date support a lower rate of these adverse events compared to placebo, though head-to-head comparisons with older agents have not been published.

Q: Has tavapadon been approved by the FDA?

No. As of the knowledge cutoff, tavapadon has not been approved by the FDA or any other regulatory agency. AbbVie submitted a New Drug Application to the FDA in September 2025 for the treatment of Parkinson's disease; the review process was pending at that time.

Q: Can I get a dose recommendation for tavapadon?

No dosing recommendation can be provided here. Tavapadon is not approved for clinical use. Published Phase 3 trials used once-daily oral doses ranging from 5 to 15 mg, but these are research protocol figures, not prescribing information. Anyone with Parkinson's disease seeking treatment options should consult a movement disorder specialist or neurologist.

Q: What were the main findings of the TEMPO Phase 3 trials?

Across the completed TEMPO trials, tavapadon demonstrated statistically significant improvements in motor outcomes (UPDRS motor subscale) versus placebo both as monotherapy in early Parkinson's disease (TEMPO-1 and TEMPO-2) and as an add-on to levodopa in patients with motor fluctuations (TEMPO-3). In the motor fluctuations trial, adjunctive tavapadon extended reliable ON time by approximately 1.7 hours versus 0.6 hours for placebo. Positive topline results were announced for all three completed trials. Full peer-reviewed publications of complete trial data may not yet be available.

Q: Is tavapadon available outside of clinical trials?

No. It is an investigational drug with no approved indication and no commercial supply. It cannot be legally prescribed or dispensed in the United States or most other jurisdictions. Participation in an ongoing clinical trial through ClinicalTrials.gov is the only lawful route of access.

Q: What are the known side effects?

In Phase 3 trials, adverse events were mostly mild to moderate. The most commonly reported were headache, nausea, and vomiting. Notably absent were significant increases in hallucinations, orthostatic hypotension, or impulse control disorders relative to placebo - findings consistent with the D1/D5-selective mechanism. Long-term safety data do not yet exist, and the full adverse event profile will be better characterized through FDA review and, if approved, post-marketing surveillance.

Not medical advice. Tavapadon is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	PF-06649751; CVL-751
Category	Research Chemical
Drug class	First-in-class D1/D5 dopamine receptor selective partial agonist
Development codes	PF-06649751 (Pfizer); CVL-751 (Cerevel Therapeutics)
Developer	Cerevel Therapeutics / AbbVie
Regulatory status	NDA submitted to US FDA September 2025; not yet approved
Key Phase 3 program	TEMPO-1, TEMPO-2, TEMPO-3, TEMPO-4 (Parkinson's disease)
Phase 3 ON-time result (adjunctive)	+1.7 hours reliable ON time vs. +0.6 hours placebo (p<0.0001, TEMPO-3)
US legal status	Investigational drug in the United States. Not approved by the FDA for any indication. A New Drug Application (NDA) was submitted to the FDA in September 2025 for the treatment of Parkinson's disease; regulatory review is pending. Not legally available for human use outside of clinical trials. Not a dietary supplement.

What is Tavapadon?

Tavapadon is a first-in-class, orally administered, D1/D5 dopamine receptor selective partial agonist under late-stage clinical investigation for Parkinson's disease. It was developed by Cerevel Therapeutics (later acquired by AbbVie) with the goal of achieving meaningful motor symptom control through a receptor selectivity profile distinct from existing dopamine agonists used in Parkinson's therapy.

How it works

Tavapadon acts as a highly selective partial agonist at D1 and D5 dopamine receptors, with minimal binding activity at D2, D3, or D4 subtypes. This selectivity preferentially engages direct-pathway medium spiny neurons in the striatum. The partial agonist design is intended to provide intrinsic activity sufficient for motor benefit while avoiding the full agonism that can produce receptor desensitization. Because impulse control disorders, excessive daytime sleepiness, and hallucinations associated with older dopamine agonists (e.g., pramipexole, ropinirole) are largely mediated through D2/D3 receptor activation, tavapadon's D1/D5 selectivity is hypothesized to reduce these adverse effects. Cardiovascular safety is also considered improved relative to early-generation D1 agonists that lacked partial agonism.

Background & history

Tavapadon originated within Pfizer's neuroscience pipeline under the development code PF-06649751. Development was later continued by Cerevel Therapeutics (Boston, MA), a company spun out of Pfizer, where it received the designation CVL-751. AbbVie subsequently acquired or partnered on Cerevel's pipeline and conducted the Phase 3 TEMPO clinical program. The NDA submission to the FDA in September 2025 represented the compound's first regulatory filing for marketing authorization. As of the knowledge cutoff, no regulatory approval has been granted by the FDA or other major agencies.

What the research says

Tavapadon has completed Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) studies in humans, demonstrating sustained motor symptom reduction lasting more than 12 hours after a once-daily 9 mg dose, with significant effect observed by approximately one hour post-administration. The Phase 3 TEMPO program comprised at least four trials: TEMPO-1 (fixed-dose, early Parkinson's disease monotherapy), TEMPO-2 (flexible-dose, early Parkinson's disease monotherapy; positive topline results announced December 2024), TEMPO-3 (adjunctive use with levodopa for motor fluctuations), and TEMPO-4 (ongoing at the time of the NDA submission). In the adjunctive levodopa trial, tavapadon at 5-15 mg once daily extended reliable ON time without troublesome dyskinesia by approximately 1.7 hours versus 0.6 hours for placebo (p less than 0.0001). Positive topline results were reported across all three completed Phase 3 trials. No safety signals for significant increases in hallucinations, orthostatic hypotension, or impulse control disorders relative to placebo were identified in reported trial data, consistent with the D1/D5 selectivity hypothesis. Human data are limited to these clinical trial contexts; no long-term post-marketing data exist.

Reported effects

Motor symptom reduction in Parkinson's disease (demonstrated in Phase 3 trials; effect size and durability based on controlled trial data only)
Extended reliable ON time when used adjunctively with levodopa (1.7 hours vs. 0.6 hours placebo in TEMPO-3; statistically significant)
Once-daily oral dosing with onset of effect approximately 1 hour post-dose and duration exceeding 12 hours (Phase 1 data)
Hypothesis-driven low incidence of impulse control disorders and hallucinations relative to D2/D3 agonists (supported by Phase 3 adverse event data but not confirmed by long-term comparative trials)
No troublesome dyskinesia increase observed in Phase 3 adjunctive trials

Dosing & administration (informational)

Published clinical trial literature reports use of 5 mg, 9 mg, and 5-15 mg once-daily oral dosing ranges in Phase 1 and Phase 3 studies. These figures are provided for informational reference to the scientific record only and do not constitute dosing guidance. Tavapadon is not approved for clinical use. Any therapeutic use must occur within a clinical trial or, if approved, under supervision of a licensed clinician who can assess individual patient factors.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Phase 3 adverse events were predominantly mild to moderate in severity
Most common reported adverse events: headache, nausea, vomiting
No significant increase in hallucinations vs. placebo in Phase 3 (consistent with D1/D5 selectivity, minimal D2/D3 engagement)
No significant orthostatic hypotension signal identified in reported Phase 3 data
No significant impulse control disorder signal identified compared to placebo
Cardiovascular safety profile described as superior to first-generation D1 agonists; no new cardiovascular concerns identified
Long-term safety data beyond Phase 3 trial durations are not yet available; post-marketing surveillance has not occurred

Drug & supplement interactions

N
o
c
o
m
p
r
e
h
e
n
s
i
v
e
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
p
r
o
f
i
l
e
h
a
s
b
e
e
n
p
u
b
l
i
c
l
y
c
h
a
r
a
c
t
e
r
i
z
e
d
.
A
s
a
d
o
p
a
m
i
n
e
a
g
o
n
i
s
t
a
c
t
i
v
e
i
n
t
h
e
s
t
r
i
a
t
u
m
,
p
h
a
r
m
a
c
o
d
y
n
a
m
i
c
i
n
t
e
r
a
c
t
i
o
n
s
w
i
t
h
o
t
h
e
r
d
o
p
a
m
i
n
e
r
g
i
c
a
g
e
n
t
s
(
l
e
v
o
d
o
p
a
,
o
t
h
e
r
d
o
p
a
m
i
n
e
a
g
o
n
i
s
t
s
,
d
o
p
a
m
i
n
e
a
n
t
a
g
o
n
i
s
t
a
n
t
i
p
s
y
c
h
o
t
i
c
s
,
a
n
t
i
e
m
e
t
i
c
s
)
a
r
e
p
l
a
u
s
i
b
l
e
.
T
E
M
P
O
-
3
s
p
e
c
i
f
i
c
a
l
l
y
s
t
u
d
i
e
d
c
o
m
b
i
n
a
t
i
o
n
w
i
t
h
l
e
v
o
d
o
p
a
a
n
d
f
o
u
n
d
n
o
a
d
d
i
t
i
v
e
d
y
s
k
i
n
e
s
i
a
s
i
g
n
a
l
i
n
r
e
p
o
r
t
e
d
d
a
t
a
,
b
u
t
t
h
i
s
d
o
e
s
n
o
t
c
o
n
s
t
i
t
u
t
e
a
f
u
l
l
i
n
t
e
r
a
c
t
i
o
n
c
h
a
r
a
c
t
e
r
i
z
a
t
i
o
n
.
C
Y
P
4
5
0
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
a
r
e
n
o
t
d
e
t
a
i
l
e
d
i
n
t
h
e
a
v
a
i
l
a
b
l
e
p
u
b
l
i
c
s
o
u
r
c
e
s
.

Who should avoid it

Do not use outside of a supervised clinical trial; no approved therapeutic context exists
Avoid combining with dopamine antagonists (certain antipsychotics, metoclopramide) - pharmacodynamic antagonism is expected
Avoid in individuals with a history of hypersensitivity to dopaminergic agents until a full safety profile is established
Avoid in pregnancy and lactation - no safety data available in these populations

How it is commonly combined

No established stacking protocols exist. TEMPO-3 studied adjunctive use with levodopa in a controlled clinical trial context, which is the only human combination data available. No evidence supports combining tavapadon with other investigational compounds outside a controlled research setting.

Legal & regulatory. Investigational drug in the United States. Not approved by the FDA for any indication. A New Drug Application (NDA) was submitted to the FDA in September 2025 for the treatment of Parkinson's disease; regulatory review is pending. Not legally available for human use outside of clinical trials. Not a dietary supplement.

Quality & harm reduction

N
o
t
c
o
m
m
e
r
c
i
a
l
l
y
a
v
a
i
l
a
b
l
e
.
T
a
v
a
p
a
d
o
n
h
a
s
o
n
l
y
b
e
e
n
a
d
m
i
n
i
s
t
e
r
e
d
i
n
t
h
e
c
o
n
t
e
x
t
o
f
r
e
g
u
l
a
t
e
d
c
l
i
n
i
c
a
l
t
r
i
a
l
s
u
n
d
e
r
i
n
v
e
s
t
i
g
a
t
i
o
n
a
l
n
e
w
d
r
u
g
(
I
N
D
)
s
t
a
t
u
s
.
N
o
c
o
m
m
e
r
c
i
a
l
s
u
p
p
l
y
c
h
a
i
n
e
x
i
s
t
s
.
R
e
s
e
a
r
c
h
o
r
g
r
a
y
-
m
a
r
k
e
t
s
o
u
r
c
i
n
g
c
a
n
n
o
t
b
e
v
e
r
i
f
i
e
d
f
o
r
i
d
e
n
t
i
t
y
o
r
p
u
r
i
t
y
a
n
d
w
o
u
l
d
c
a
r
r
y
u
n
k
n
o
w
n
r
i
s
k
.

Find Tavapadon →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

What makes tavapadon different from older Parkinson's drugs like pramipexole or ropinirole?

Older dopamine agonists used in Parkinson's disease primarily target D2 and D3 receptors. D3 agonism in particular is associated with impulse control disorders and excessive daytime sleepiness. Tavapadon selectively targets D1 and D5 receptors instead, which is hypothesized to provide motor benefit through the direct striatal pathway while avoiding D2/D3-driven side effects. Phase 3 trial data to date support a lower rate of these adverse events compared to placebo, though head-to-head comparisons with older agents have not been published.

Has tavapadon been approved by the FDA?

No. As of the knowledge cutoff, tavapadon has not been approved by the FDA or any other regulatory agency. AbbVie submitted a New Drug Application to the FDA in September 2025 for the treatment of Parkinson's disease; the review process was pending at that time.

Can I get a dose recommendation for tavapadon?

No dosing recommendation can be provided here. Tavapadon is not approved for clinical use. Published Phase 3 trials used once-daily oral doses ranging from 5 to 15 mg, but these are research protocol figures, not prescribing information. Anyone with Parkinson's disease seeking treatment options should consult a movement disorder specialist or neurologist.

What were the main findings of the TEMPO Phase 3 trials?

Across the completed TEMPO trials, tavapadon demonstrated statistically significant improvements in motor outcomes (UPDRS motor subscale) versus placebo both as monotherapy in early Parkinson's disease (TEMPO-1 and TEMPO-2) and as an add-on to levodopa in patients with motor fluctuations (TEMPO-3). In the motor fluctuations trial, adjunctive tavapadon extended reliable ON time by approximately 1.7 hours versus 0.6 hours for placebo. Positive topline results were announced for all three completed trials. Full peer-reviewed publications of complete trial data may not yet be available.

Is tavapadon available outside of clinical trials?

No. It is an investigational drug with no approved indication and no commercial supply. It cannot be legally prescribed or dispensed in the United States or most other jurisdictions. Participation in an ongoing clinical trial through ClinicalTrials.gov is the only lawful route of access.

What are the known side effects?

In Phase 3 trials, adverse events were mostly mild to moderate. The most commonly reported were headache, nausea, and vomiting. Notably absent were significant increases in hallucinations, orthostatic hypotension, or impulse control disorders relative to placebo - findings consistent with the D1/D5-selective mechanism. Long-term safety data do not yet exist, and the full adverse event profile will be better characterized through FDA review and, if approved, post-marketing surveillance.

References & further reading

PubMed: tavapadon D1/D5 dopamine partial agonist Parkinson rationale development (PMID 36999711)
PubMed: tavapadon pharmacokinetics pharmacodynamics safety phase 1 dopamine D1/D5
ClinicalTrials.gov: NCT04201093 (TEMPO-1, tavapadon early Parkinson fixed dose)
ClinicalTrials.gov: NCT04223193 (TEMPO-2, tavapadon early Parkinson flexible dose)
ClinicalTrials.gov: NCT04542499 (TEMPO-3, tavapadon adjunctive levodopa motor fluctuations)